Sarpogrelate hydrochloride


Concise Prescribing Info
Indications/Uses
Chronic arterial occlusion.
Dosage/Direction for Use
Adult : PO 100 mg tid, may be adjusted as required.
Dosage Details
Oral
Chronic arterial occlusion
Adult: 100 mg tid, may be adjusted according to age and symptoms.
Elderly: May reduce to 150 mg daily.
Contraindications
Haemorrhage, including gastrointestinal ulceration, urinary tract haemorrhage, haemophilia, capillary fragility, haemoptysis, vitreous haemorrhage. Pregnancy.
Special Precautions
Patient with haemorrhagic diathesis, bleeding tendency (e.g. gastrointestinal ulcer, haemoptysis, urinary tract haemorrhage, vitreous haemorrhage),or menstrual period. Severe renal impairment. Elderly. Lactation.
Adverse Reactions
Significant: Cerebral and gastrointestinal haemorrhage, thrombocytopenia, agranulocytosis, jaundice, increased AST/ALT and bilirubin.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Palpitations, breath shortness, chest pain.
Gastrointestinal disorders: Abdominal pain, nausea, heartburn, constipation, anorexia, diarrhoea.
General disorders and administration site conditions: Malaise.
Investigations: Increased blood triglycerides and cholesterol, decreased serum albumin and serum calcium, increased weight.
Metabolism and nutrition disorders: Oedema.
Nervous system disorders: Headache, dizziness, taste abnormality.
Psychiatric disorders: Sleepiness.
Renal and urinary disorders: Proteinuria, increased BUN and creatinine, urinary sugar, abnormal urinary sediment.
Respiratory, thoracic and mediastinal disorders: Epistaxis.
Skin and subcutaneous tissue disorders: Rash, redness, pruritus.
Vascular disorders: Hot flush.
MonitoringParameters
Monitor for abnormal haemorrhage and LFT.
Drug Interactions
Increased risk of bleeding with anticoagulants (e.g. warfarin) and antiplatelets (e.g. cilostazol, aspirin, ticlodipine).
Action
Description: Sarpogrelate hydrochloride inhibits platelet aggregation and vascular contraction through antagonistic action to 5-HT2 serotonin receptor in platelets and vascular smooth muscle thereby preventing blood clot formation and improving blood flow.
Pharmacokinetics:
Metabolism: Deesterified and further metabolised by multiple CYP enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
Excretion: Via urine (44.5%) and faeces (4.2%).
Chemical Structure

Chemical Structure Image
Sarpogrelate hydrochloride

Source: National Center for Biotechnology Information. PubChem Database. Sarpogrelate hydrochloride, CID=444005, https://pubchem.ncbi.nlm.nih.gov/compound/Sarpogrelate-hydrochloride (accessed on Jan. 23, 2020)

Storage
Store between 20-25°C. Protect from light and moisture.
References
Buckingham R (ed). Sarpogrelate Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/05/2018 .

Disclaimer: This information is independently developed by MIMS based on Sarpogrelate hydrochloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in